nChroma Bio
nChroma Bio is a genetic medicines company focused on developing targeted in vivo therapies that combine gene-regulating cargos with tissue-directed delivery technologies. The organization advances epigenetic editing approaches and multiple non-viral delivery modalities through preclinical work and early-stage clinical development, with an initial clinical program targeting chronic hepatitis B.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
CRMA-1001 (clinical-stage liver-directed epigenetic silencer)
Clinical-stage epigenetic editor designed to durably silence hepatitis B virus antigen expression and HBV replication by targeted DNA methylation of cccDNA and integrated HBV DNA without cutting the genome.
CRMA-1001 (clinical-stage liver-directed epigenetic silencer)
Clinical-stage epigenetic editor designed to durably silence hepatitis B virus antigen expression and HBV replication by targeted DNA methylation of cccDNA and integrated HBV DNA without cutting the genome.
Services
Preclinical target validation, in vivo pharmacology and safety studies, assay development for specificity, and translational activities to advance candidates toward clinical entry.
Preclinical target validation, in vivo pharmacology and safety studies, assay development for specificity, and translational activities to advance candidates toward clinical entry.
Expertise Areas
- Epigenetic editing and gene regulation
- In vivo targeted delivery
- Preclinical pharmacology and safety
- Early-phase clinical development
Key Technologies
- Epigenetic editors (DNA methylation-based gene regulation)
- Non-viral programmable delivery vehicles
- Engineered virus-like particles (VLPs)
- AAV vector delivery
News & Updates
Announcement that the first participant was dosed in the open-label Phase 1/2 study assessing safety, PK/PD and efficacy of the clinical-stage epigenetic silencer for chronic hepatitis B; additional CTAs approved in New Zealand and the UK.
Regulatory clearance (Certificate for Clinical Trial) to initiate a Phase 1/2 clinical trial for the company's lead epigenetic silencer for chronic hepatitis B.
Merger of two organizations to form the company and completion of a $75 million financing to support platform and pipeline development.
Acceptance of oral and poster abstracts covering multiplex HSPC editing and engineered virus-like particles for presentation at the ASGCT 2025 Annual Meeting.
Multiple abstracts accepted, including a poster of distinction describing preclinical pharmacology and safety of the lead epigenetic editor showing HBV surface antigen loss in animal models.
Lead epigenetic silencer advanced to Phase 1/2 and first patient dosed.
Announcement that the first participant was dosed in the open-label Phase 1/2 study assessing safety, PK/PD and efficacy of the clinical-stage epigenetic silencer for chronic hepatitis B; additional CTAs approved in New Zealand and the UK.
Regulatory clearance (Certificate for Clinical Trial) to initiate a Phase 1/2 clinical trial for the company's lead epigenetic silencer for chronic hepatitis B.
Merger of two organizations to form the company and completion of a $75 million financing to support platform and pipeline development.
Acceptance of oral and poster abstracts covering multiplex HSPC editing and engineered virus-like particles for presentation at the ASGCT 2025 Annual Meeting.
Multiple abstracts accepted, including a poster of distinction describing preclinical pharmacology and safety of the lead epigenetic editor showing HBV surface antigen loss in animal models.
Lead epigenetic silencer advanced to Phase 1/2 and first patient dosed.